Studies of catecholamine metabolism in schizophrenia/psychosis-I

James W. Maas, Salvador A. Contreras, Alexander L. Miller, Nancy Bennan, Charles L. Bowden, Martin A. Javors, Emiias Seleshi, Susan Weintraub

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Acutely psychotic schizophrenic patients not taking antipsychotic medications and control subjects were studied before and during treatment with debrisoquin (DBQ), an inhibitor of monoamine oxidase, which does not penetrate into brain. Homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were measured in plasma, urine, and cerebrospinal fluid (CSF). Significant differences between patients and control subjects were more easily discerned during treatment with DBQ. In patients, HVA was increased in plasma but not in urine or CSF, although MHPG was increased in all three fluids. There were many significant correlations between plasma MHPG and HVA levels and clinical ratings of psychoticism. Plasma MHPG correlated positively with both the severity of positive and negative symptoms and plasma HVA correlated only with positive symptom severity. These data suggest that both dopamine and norepinephrine (NE) metabolism are disturbed in acutely psychotic schizophrenic patients, disturbed NE metabolism may relate to negative symptoms as well.

Original languageEnglish (US)
Pages (from-to)97-109
Number of pages13
JournalNeuropsychopharmacology
Volume8
Issue number2
DOIs
StatePublished - Feb 1993

Keywords

  • Dopamine
  • Hva
  • Mhpg
  • Neuroleptic actions
  • Norepinephrine
  • Psychosis
  • Renal clearance
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Studies of catecholamine metabolism in schizophrenia/psychosis-I'. Together they form a unique fingerprint.

Cite this